TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12374444

Group type: EXPERIMENTAL
Intervention: Protestant participants in a work context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male Protestant participants in a work setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male Protestant participants in a nonwork setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women participants (both Protestant and non-Protestant)
Number of subjects: 0
Study: 10428349

Group type: EXPERIMENTAL
Intervention: Color Doppler energy (CDE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CDE during treatment
Number of subjects: 19
Study: 9651714

Group type: EXPERIMENTAL
Intervention: Basic clinical parameters, ECG, and exercise test
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ST depression > or = 0.1 mV
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low maximum workload at exercise test
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ST T-changes at early exercise test
Number of subjects: 200
Study: 1681365

Group type: EXPERIMENTAL
Intervention: Liquid formulation of Ty21a vaccine
Number of subjects: 20543

Group type: EXPERIMENTAL
Intervention: Enteric coated capsules of Ty21a vaccine
Number of subjects: 20543

Group type: COMPARATOR
Intervention: Placebo (liquid formulation)
Number of subjects: 20543
Study: 6345649

Group type: EXPERIMENTAL
Intervention: Mepenzolate bromide (MZB) 50 mg, taken 4 times daily for 48 hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo, taken 4 times daily for 48 hours
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mepenzolate bromide (MZB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31575091

Group type: EXPERIMENTAL
Intervention: Selenium (200 µg) and Coenzyme Q10 (200 mg) daily for four years
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 30278569

Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 27080343

Group type: EXPERIMENTAL
Intervention: Honeybee LAB microbiome (a mixture of 9 Lactobacillus spp. and 4 Bifidobacterium spp.)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Honeybee LAB microbiome
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 22
Study: 24622750

Group type: EXPERIMENTAL
Intervention: Indirect infant supplementation (400 mg iodine to the mother, placebo to the infant)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Direct infant supplementation (100 mg iodine to the infant, placebo to the mother)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Indirect infant supplementation
Number of subjects: 241

Group type: COMPARATOR
Intervention: Direct infant supplementation
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 241
Study: 23158178

Group type: EXPERIMENTAL
Intervention: CA4P arm (carboplatin/paclitaxel with CA4P)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control arm (carboplatin/paclitaxel without CA4P)
Number of subjects: 80
Study: 20218995

Group type: EXPERIMENTAL
Intervention: 5 IU oxytocin bolus and 30 IU infusion
Number of subjects: 720

Group type: COMPARATOR
Intervention: 5 IU oxytocin bolus and placebo
Number of subjects: 720
Study: 19029269

Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (APG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Gelatine (CONT)
Number of subjects: 64
Study: 15812262

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Citalopram (40 mg/day)
Number of subjects: 280
Study: 12458821

Group type: EXPERIMENTAL
Intervention: Coxibs (celecoxib and rofecoxib)
Number of subjects: 0
Study: 10357338

Group type: COMPARATOR
Intervention: 20 mL of alkalinized lidocaine with 0 microg phenylephrine (Group 1)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 20 mL of alkalinized lidocaine with 50 microg phenylephrine (Group 2)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 20 mL of alkalinized lidocaine with 100 microg phenylephrine (Group 3)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 20 mL of alkalinized lidocaine with 200 microg phenylephrine (Group 4)
Number of subjects: 81
Study: 8546442

Group type: EXPERIMENTAL
Intervention: CH + MCT/LCT regimen
Number of subjects: 24

Group type: COMPARATOR
Intervention: CH regimen
Number of subjects: 24
Study: 1672870

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/ACTH treatment
Number of subjects: 0
Study: 7033673

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 161

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 29172994

Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg daily for 5 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28877705

Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26363005

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 610
Study: 23998168

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs) prescribed, including amitriptyline, dextropropoxyphene, quinine, and benzodiazepines.
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Significant depressive symptoms (Geriatric Depression Scale ≥5)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Comparison of inappropriate medication use between those with and without significant depressive symptoms
Number of subjects: 191
Study: 21283922

Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.1% cream applied once daily for two weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vehicle applied once daily for two weeks (control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.1% cream
Number of subjects: 25
Study: 19722789

Group type: EXPERIMENTAL
Intervention: Submarginal free gingival grafts (SMFGGs)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Marginal free gingival grafts (MFGGs)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (untreated homologous sites)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Treated sites
Number of subjects: 55

Group type: COMPARATOR
Intervention: Treated and untreated sites
Number of subjects: 55
Study: 17549479

Group type: EXPERIMENTAL
Intervention: Gemcitabine at standard rate (1,200 mg/m2 over 30 min) + Carboplatin (AUC of 5 over 4 h)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Gemcitabine at fixed dose rate (1,200 mg/m2 over 120 min) + Carboplatin (AUC of 5 over 4 h)
Number of subjects: 42
Study: 15545310

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalexin with ranitidine or omeprazole
Number of subjects: 0
Study: 11684971

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia combined with light general anesthesia and postoperative epidural patient-controlled analgesia
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia combined with light general anesthesia and postoperative intravenous patient-controlled analgesia
Number of subjects: 168

Group type: COMPARATOR
Intervention: General anesthesia alone with postoperative epidural patient-controlled analgesia
Number of subjects: 168

Group type: COMPARATOR
Intervention: General anesthesia alone with postoperative intravenous patient-controlled analgesia
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Epidural patient-controlled analgesia
Number of subjects: 168

Group type: COMPARATOR
Intervention: General anesthesia with postoperative analgesia
Number of subjects: 168
Study: 9831221

Group type: EXPERIMENTAL
Intervention: Mepartricin 40 mg/daily
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 8008537

Group type: EXPERIMENTAL
Intervention: General ultrasound screening
Number of subjects: 11925

Group type: COMPARATOR
Intervention: Selective ultrasound screening
Number of subjects: 11925

Group type: COMPARATOR
Intervention: No ultrasound screening
Number of subjects: 11925
Study: 2245667

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 6251939

Group type: EXPERIMENTAL
Intervention: Prolene
Number of subjects: 347

Group type: COMPARATOR
Intervention: Dexon
Number of subjects: 347
Study: 30624425

Group type: EXPERIMENTAL
Intervention: Pediatric mHealth app
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Low literacy pediatric health book with video
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both book and app
Number of subjects: 98

Group type: COMPARATOR
Intervention: Car-seat safety video and handout
Number of subjects: 98
Study: 31247504

Group type: EXPERIMENTAL
Intervention: Opioid agonist treatment (OAT)
Number of subjects: 1283

Group type: COMPARATOR
Intervention: Non-opioid agonist treatment (non-OAT)
Number of subjects: 1283
Study: 27866988

Group type: EXPERIMENTAL
Intervention: 50% PSR with an advanced wake-time
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (habitual bed- and wake-time)
Number of subjects: 18
Study: 25431430

Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Treatment as usual (primarily individual-based CBT)
Number of subjects: 215
Study: 24251120

Group type: EXPERIMENTAL
Intervention: Resistive exercise (RE)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistive exercise with superimposed vibration stimuli (RVE)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 23
Study: 21444867

Group type: EXPERIMENTAL
Intervention: Pelvic external-beam radiotherapy (EBRT)
Number of subjects: 714

Group type: COMPARATOR
Intervention: No additional treatment (NAT)
Number of subjects: 714
Study: 19299776

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pregabalin 75-300 mg
Number of subjects: 108
Study: 17708607

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) therapy for 3 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 42
Study: 15087291

Group type: EXPERIMENTAL
Intervention: 2 g intravenous ascorbic acid (AA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11600169

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation with Guided Imagery
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study: 9738388

Group type: EXPERIMENTAL
Intervention: Theophylline plus BDP 400 micrograms/day
Number of subjects: 133

Group type: COMPARATOR
Intervention: BDP 800 micrograms/day
Number of subjects: 133
Study: 8048508

Group type: EXPERIMENTAL
Intervention: Chloroquine 250 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chloroquine 500 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2567740

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg qid
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 182105

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing factor (TRF) 43 mg daily for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30621326

Group type: EXPERIMENTAL
Intervention: Teaching Assistant-led after-school physical activity programme for 15 weeks
Number of subjects: 335

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Teaching Assistant-led after-school physical activity programme
Number of subjects: 335

Group type: COMPARATOR
Intervention: Existing provision in the 12 schools
Number of subjects: 335
Study: 27680604

Group type: EXPERIMENTAL
Intervention: Full-thickness CK7 staining
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: HPV16 status
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Antecedent high-grade cytology
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: p16 IHC
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Gradation/'top-down' CK7 pattern
Number of subjects: 517
Study: 25887463

Group type: EXPERIMENTAL
Intervention: Catastrophizing reduction manipulation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (pain education)
Number of subjects: 113
Study: 24283084

Group type: EXPERIMENTAL
Intervention: 2.5 mg of spinal plain bupivacaine only (Group B)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 2.5 mg plain bupivacaine with 25 mcg of fentanyl (Group BF)
Number of subjects: 112
Study: 21904105

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 18798807

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Reduction in pain levels
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Time taken to return to normal activities after treatment
Number of subjects: 1198
Study: 16421404

Group type: EXPERIMENTAL
Intervention: SonoVue 2.4 ml
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: SonoVue (various doses: 0.3 ml, 0.6 ml, 1.2 ml, 2.4 ml)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: SonoVue
Number of subjects: 82
Study: 15285725

Group type: EXPERIMENTAL
Intervention: Pooled buffy-coat platelet components prepared in reduced (35%) plasma content
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platelet components suspended in 100% plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: T-Sol control platelet components mixed with plasma
Number of subjects: 0
Study: 11745947

Group type: EXPERIMENTAL
Intervention: Abnormal median sensory latencies
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 9294681

Group type: EXPERIMENTAL
Intervention: Keratometry-style readings (K)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Post-radial keratotomy (RK)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Post-excimer laser photorefractive keratectomy (PRK)
Number of subjects: 208
Study: 8343473

Group type: EXPERIMENTAL
Intervention: Mitomycin C 0.4 mg/ml (0.04%) eye drops, four times a day for 2 weeks post-surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bare sclera technique for pterygium excision
Number of subjects: 30
Study: 3534140

Group type: EXPERIMENTAL
Intervention: vidarabine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: acyclovir
Number of subjects: 38
Study: 30167757

Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice on day 1 and 200 mg twice on days 2-5)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26104432

Group type: EXPERIMENTAL
Intervention: Step-down treatment program (short-term day-hospital treatment followed by outpatient combined group and individual psychotherapy)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Outpatient individual psychotherapy
Number of subjects: 79
Study: 25588402

Group type: EXPERIMENTAL
Intervention: Scalpel method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erbium laser
Number of subjects: 0
Study: 22836071

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2-4 mg/day (PITA, n = 97)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Atorvastatin 10-20 mg/day (ATOR, n = 92)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pitavastatin (n = 68)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Atorvastatin (n = 67)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pitavastatin (n = 18)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Atorvastatin (n = 20)
Number of subjects: 189
Study: 20831782

Group type: EXPERIMENTAL
Intervention: Routine replacement every 3 days
Number of subjects: 362

Group type: COMPARATOR
Intervention: Clinically indicated resite
Number of subjects: 362
Study: 18778758

Group type: EXPERIMENTAL
Intervention: Levo-Form 1 (matrix)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Levo-Form 2 (coated)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prolopa HBS 125 (marketed product)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Benserazide (inhibitor of extracerebral dopa decarboxylase)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbidopa (inhibitor of extracerebral dopa decarboxylase)
Number of subjects: 10
Study: 16154437

Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin (HC) 1 mg intravenous weekly for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyanocobalamin (CC) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crossover to alternate form (HC or CC)
Number of subjects: 0
Study: 14559955

Group type: EXPERIMENTAL
Intervention: Reducing Disability in Alzheimer Disease (RDAD) program
Number of subjects: 153

Group type: COMPARATOR
Intervention: Routine Medical Care (RMC)
Number of subjects: 153
Study: 10765065

Group type: EXPERIMENTAL
Intervention: Finasteride (5α-reductase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GI198745 (dual 5α-reductase inhibitor)
Number of subjects: 0
Study: 8895267

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fentanyl anesthesia
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 44
Study: 2049752

Group type: EXPERIMENTAL
Intervention: POG protocol 8303 (four-drug systemic reinduction: prednisone, vincristine, daunorubicin, and asparaginase; brief intensive consolidation with teniposide and cytarabine; continuation chemotherapy with weekly rotating drug pairs; bilateral testicular radiation (2600 cGy); intrathecal chemoprophylaxis every 4 to 6 weeks)
Number of subjects: 38
Study: 6589968

Group type: EXPERIMENTAL
Intervention: Cranial radiation and chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 50

Group type: COMPARATOR
Intervention: Longer duration of chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Younger age at the time of radiation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dose of cranial radiation, concomitant intrathecal methotrexate therapy, and duration of therapy
Number of subjects: 50
Study: 31533863

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 250

Group type: COMPARATOR
Intervention: Not surgery (control)
Number of subjects: 250
Study: 29785146

Group type: EXPERIMENTAL
Intervention: Asthma question prompt list with video intervention
Number of subjects: 359

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 359
Study: 27621597

Group type: COMPARATOR
Intervention: AZD1981 1,000 mg bid
Number of subjects: 719

Group type: COMPARATOR
Intervention: AZD1981 50 mg bid
Number of subjects: 719

Group type: COMPARATOR
Intervention: AZD1981 400 mg bid
Number of subjects: 719
Study: 24355040

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg
Number of subjects: 211
Study: 23026854

Group type: EXPERIMENTAL
Intervention: Webcam intervention (telepsychiatry)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 167
Study: 21051656

Group type: EXPERIMENTAL
Intervention: 0.5 mg lasofoxifene
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8556
Study: 18052570

Group type: EXPERIMENTAL
Intervention: Risperidone (2 to 4 mg/day for 1 year)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Haloperidol (2 to 4 mg/day for 1 year)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Risperidone and Haloperidol
Number of subjects: 159
Study: 16047123

Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg) administered intravenously 3 min prior to treadmill stress
Number of subjects: 86

Group type: COMPARATOR
Intervention: No atropine administered (Control)
Number of subjects: 86
Study: 12475854

Group type: EXPERIMENTAL
Intervention: Five different bilevel pressure home ventilators
Number of subjects: 28
Study: 9565927

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (ET) for 6 months, including lumbar extension (MedX) 1 day/week and variable resistance exercises (Nautilus) 2 days/week.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no exercise training) for 6 months.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (ET) for 6 months.
Number of subjects: 14
Study: 7625665

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (OPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined diphtheria and tetanus toxoids and pertussis vaccine with IPV
Number of subjects: 0
Study: 2515822

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (acylated streptokinase, intravenous bolus of 30 units in 4 minutes)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 100
Study: 823725

Group type: EXPERIMENTAL
Intervention: Dipyridamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast medium
Number of subjects: 0
Study: 31727650

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia Awareness Restoration Programme despite optimised care (HARPdoc)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Blood Glucose Awareness Training (BGAT)
Number of subjects: 28